PR Newswire
The news release titled "2026 ESMO LBA | Innovent Announces International Phase 3 Study of Arcotatug Tavatecan (CLDN18.2-ADC) in Gastric Cancer Met Dual Primary Endpoints of PFS and OS" issued 23-Oct-2026 is being retracted and should be disregarded. It was distributed in error timing and was not intentional.
SOURCE Innovent Biologics
